Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials
Authors
Keywords
Statin, Statin Therapy, Ezetimibe, Cholesteryl Ester Transfer Protein, Weighted Mean Difference
Journal
American Journal of Cardiovascular Drugs
Volume 14, Issue 5, Pages 367-376
Publisher
Springer Nature
Online
2014-06-11
DOI
10.1007/s40256-014-0077-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
- (2011) Allan D. Sniderman et al.
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Antisense therapy and emerging applications for the management of dyslipidemia
- (2011) Peter P. Toth Journal of Clinical Lipidology
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease
- (2010) Harold E. Bays et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
- (2009) Maartje E. Visser et al. JOURNAL OF LIPID RESEARCH
- Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
- (2009) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective Data
- (2008) Anna Bennet ARCHIVES OF INTERNAL MEDICINE
- Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients
- (2008) Christie M. Ballantyne et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started